In AD participants, the increased levels of t‐tau and p‐tau 181 in CSF from APOE ε4 carriers aligned with previous studies, which suggested that APOE ε4 may be associated with tau pathology and thus leading to more progressive type of AD [21, 22]. The gene discussed is MAPT; the disease is Alzheimer disease.